Alnylam to secure up to $2bn from Blackstone
Blackstone has agreed to provide up to $2 billion to Cambridge, Massachusetts-based Alnylam Pharmaceuticals Inc, a RNAi therapeutics company.
13 April 2020•7 mins read
Blackstone has agreed to provide up to $2 billion to Cambridge, Massachusetts-based Alnylam Pharmaceuticals Inc, a RNAi therapeutics company.
HIG Capital’s Vernacare adds UK medical device businesses Bailey and ASep
1 hour ago · 2 mins read
Paradigm Equity Partners acquires upholstery and performance fabric maker STI Fabrics
17 hours ago · 1 min read
KKR and Hildred merge diagnostics businesses Sapphiros and binx health into Onvaro
17 hours ago · 2 mins read
Eir Partners-backed Porter acquires health plan analytics firm Pareto Intelligence
18 hours ago · 1 min read
Bain Capital’s LeanTaaS snaps up hospital care transition platform Aidin
18 hours ago · 2 mins read
Carlyle-backed Vantive agrees hemodialysis business sale to Rockwell Medical
18 hours ago · 2 mins read
Novacap completes OSI Maritime Systems acquisition as first Fund VII deal
18 hours ago · 2 mins read
